Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial

Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprote...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Neurol
Autores principales: Dörr, Jan, Wernecke, Klaus-Dieter, Würfel, Jens, Bellmann-Strobl, Judith, Siffrin, Volker, Sättler, Muriel B., Simons, Mikael, Linsa, Andreas, Tumani, Hayrettin, Paul, Friedemann
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2018
Materias:
Neurology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6190842/
https://ncbi.nlm.nih.gov/pubmed/30356868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2018.00842
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares